TD Cowen Maintains Protara Therapeutics(TARA.US) With Buy Rating
H.C. Wainwright Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $23
Protara Therapeutics Analyst Ratings
Oppenheimer Maintains Protara Therapeutics(TARA.US) With Buy Rating, Cuts Target Price to $25
Oppenheimer Sticks to Their Buy Rating for Protara Therapeutics (TARA)
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), MoonLake Immunotherapeutics (MLTX) and Protara Therapeutics (TARA)
TD Cowen Maintains Protara Therapeutics(TARA.US) With Buy Rating
Protara Therapeutics Analyst Ratings
Protara Therapeutics Analyst Ratings
Protara Therapeutics Analyst Ratings
Protara Therapeutics (TARA) Receives a Buy From Oppenheimer
Protara Therapeutics Analyst Ratings
Protara Therapeutics Analyst Ratings
Protara Therapeutics Analyst Ratings
Analysts Conflicted on These Healthcare Names: Cadrenal Therapeutics, Inc. (CVKD), Protara Therapeutics (TARA) and Spruce Biosciences (SPRB)
Oppenheimer Reaffirms Their Buy Rating on Protara Therapeutics (TARA)
Analysts Conflicted on These Healthcare Names: Protara Therapeutics (TARA), Cybin (CYBN) and Roche Holding AG (OtherRHHVF)
Oppenheimer Adjusts Protara Therapeutics Price Target to $26 From $30, Maintains Outperform Rating
Analysts' Opinions Are Mixed on These Healthcare Stocks: Amarin (AMRN), Protara Therapeutics (TARA) and Incyte (INCY)
Oppenheimer Remains a Buy on Protara Therapeutics (TARA)